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Infectious pathogens have long been recognized as potentially powerful agents impacting on the
evolution of human genetic diversity. Analysis of large-scale case–control studies provides one of
the most direct means of identifying human genetic variants that currently impact on susceptibility
to particular infectious diseases. For over 50 years candidate gene studies have been used to identify
loci for many major causes of human infectious mortality, including malaria, tuberculosis, human
immunodeﬁciency virus/acquired immunodeﬁciency syndrome, bacterial pneumonia and hepatitis.
But with the advent of genome-wide approaches, many new loci have been identiﬁed in diverse
populations. Genome-wide linkage studies identiﬁed a few loci, but genome-wide association
studies are proving more successful, and both exome and whole-genome sequencing now offer a
revolutionary increase in power. Opinions differ on the extent to which the genetic component to
common disease susceptibility is encoded by multiple high frequency or rare variants, and the her-
etical view that most infectious diseases might even be monogenic has been advocated recently.
Review of ﬁndings to date suggests that the genetic architecture of infectious disease susceptibility
may be importantly different from that of non-infectious diseases, and it is suggested that natural
selection may be the driving force underlying this difference.
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1. WHY STUDY THE GENETICS OF INFECTIOUS
DISEASE SUSCEPTIBILITY?
Studies of genetic susceptibility to infectious diseases
in humans have a long history, starting with blood
groups and other phenotypic markers and a striking
success in the early 1950s with the identiﬁcation of
the sickle haemoglobin variant as a major resistance
factor for malaria [1]. Today, a great variety of
approaches are used from twin studies to whole-
genome sequencing. These efforts have several goals.
Foremost is a better understanding of disease patho-
genesis and resistance in the expectation that this
will lead, in time, to improved interventions such as
better drugs or vaccines to prevent or attenuate the
great global burden of infectious disease morbidity
and mortality. With over 10 million deaths annually
frominfectious diseasesandthethreatofnewepidemics
and pandemics, this is a very high priority. There are
clear examples where human genetic research has sup-
ported the development of new drugs and vaccines.
A recently introduced class of human immunodeﬁ-
ciency virus (HIV) drugs known as entry inhibitors
were developed in part based on the knowledge that a
speciﬁc deletion in the gene for the CCR5 co-receptor
greatly reduced the risk of HIV infection and the rate
of disease progression after infection [2]. The leading
vaccine candidate for Plasmodium vivax malaria [3],
the Duffy bindingprotein,was identiﬁed and developed
supported by evidence that genetic absence of its red
blood cell entry receptor provides almost complete
protection from this type of malaria [4]. Awareness
of the prevalence of a common immunodeﬁciency
of mannose-binding lectin, conferring increased risk of
bacterial disease, has encouraged the development
of replacement therapy [5].
A second application that is gaining increasing
attention is the potential to stratify populations for
risk of infectious disease based on genetic proﬁling.
This has not been a priority until now as most preven-
tive interventions such as childhood vaccines have
been aimed at universal coverage. However, as more
potentially useful vaccines are licensed and the costs
of new vaccines escalate, targeted use is becoming a
consideration. When a genetic proﬁle costs less than
a vaccine and the proﬁle has many other applications
in predicting disease risk, it may well be cost-effective
to target newer vaccines to those who will beneﬁt most
from them. The recent awareness that low-frequency
large-effect variants may make a large contribution to
inter-individual genetic variation in susceptibility to
many diseases [6] should increase interest in deﬁning,
early in life, the constellation of potentially deleterious
variants that comprise an individual’s inheritance.
But the third, and one of the most interesting
aspects of this ﬁeld, is that most relevant to the
theme of this issue. The evolutionary signiﬁcance of
genetic variation in susceptibility to infection has
long fascinated the public as well as physicians and
infection specialists. Questions such as the importance
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the great diversity that we can now readily deﬁne in our
genomes have long been debated. I will discuss some
aspects of evolutionary interest towards the end of this
review, after ﬁrst providing an overview of approaches
and recent progress in this ﬁeld. The focus will be on
information that has been provided by large well-
designed case–control studies, which have provided
themostcompellingevidenceoftherelevanceofspeciﬁc
genetic variants to infectious disease susceptibility.
2. INFECTIOUS DISEASE SUSCEPTIBILITY
IS GENETICALLY CONTROLLED
There are some well-studied examples of familial clus-
tering of severe infectious disease syndromes, and
these very rare monogenic disorders have been
reviewed elsewhere [7]. A more challenging question
is the extent to which common major infectious dis-
eases are affected by host genetics. Here, the
standard genetic measure used for complex traits,
lambda-s, a measure of the increase in risk to siblings
of an affected case compared with an unrelated indi-
vidual, is confounded by the tendency of people to
live with their relatives, so that dissecting the effect
of environment from shared genes become very difﬁ-
cult. A better approach is to compare the
concordance of disease in fraternal and identical twin
pairs, where a greater concordance in the latter pro-
vides a measure of heritability. Such studies have
been undertaken for several infectious diseases, usually
many years ago, and a relatively consistent picture of
signiﬁcant heritability for chronic infectious diseases
emerges. The evidence is less clear for acute infections
such as measles, where exposure and infection rates
were very high when these early twin studies were per-
formed [8]. But in tuberculosis [9], leprosy [10],
Helicobacter pylori infection [11], chronic hepatitis B
infection [12] as well as in the phenotype of immune
responses to vaccination [13,14], there is evidence of
greater concordance in monozygotic compared with
dizygotic twin pairs.
3. APPROACHES TO GENE IDENTIFICATION
One of the most interesting aspects of this ﬁeld is the
wide variety of approaches that can be, and have been,
taken towards identiﬁcation of relevant susceptibility
genes for infectious diseases.
Some have advocated the use of animal models of
infectious diseases as a route to ﬁnding human infec-
tious diseases susceptibility loci [15]. It is clear that
rodent strains can differ strikingly in susceptibility to
infections and genes can be mapped and identiﬁed in
controlled challenge studies. The difﬁculty has been
in extrapolating these ﬁndings to humans who will
often not show comparable polymorphism in the rel-
evant loci or may even lack a homologous gene.
A related approach is to deﬁne the susceptibility proﬁle
of artiﬁcially generated knockout mice. Such efforts
continue and are clearly of value in identifying pathways
of potential relevance to human infectious disease sus-
ceptibility, but in terms of actual deﬁnition of known
human susceptibility loci, very few of these have
emerged from animal model analysis. Recently, a tuber-
culosis susceptibility gene was suggested by an analysis
of zebraﬁsh genetics [16], but the homologous gene was
not associated with human tuberculosis susceptibility in
a very large study of over 3700 clinical cases [17].
Prior to the availability of genome-wide association
technologies, linkage mapping was attempted to map
major genes in common infectious diseases. This
required the laborious collection of families with mul-
tiple cases, usually affected sibling pairs, and the use of
microsatellite markers to deﬁne chromosomal seg-
ments segregating with disease. It was possible to
identify a small number of regions linked to leprosy
[18–20], tuberculosis [21,22] and chronic hepatitis
[23] in these family studies and some positional candi-
date genes were associated with disease. But it has
been difﬁcult to deﬁne the mapped loci in large-scale
association studies and to date none appears to have
been independently conﬁrmed. These searches for
genetic loci of very large effect that might be detectable
in such small-scale linkage studies were encouraged by
a form of pedigree analysis known as complex segre-
gation analysis, which was claimed to identify the
existence (but not the location) of major loci for
many infectious diseases [24,25]. However, the clear-
est result from these genome-wide linkage studies is
that such prevalent major genes must be very rare in
infectious diseases, in contrast to some autoimmune
diseases where major loci, especially in the human leu-
cocyte antigen (HLA) complex, could be detected by
affected sibling pair studies. In summary, the central
problem with this approach is that most infectious dis-
ease susceptibility genes have too small effect sizes
and/or too low a frequency to allow detection in link-
age studies of even hundreds of families.
After this foray into family studies, the ﬁeld returned
to association studies of infectious disease susceptibility
comparing the frequency of variants in affected cases
with those of healthy controls. Ever since the successful
identiﬁcationofsicklehaemoglobinasaresistancelocus
in the 1950s [1], and extensive blood group association
studies in the 1960s [26], such case–control studies
have been the most widely used and most successful
approach to identifying convincing infectious disease
susceptibility genes in humans.
However, the very simplicity of the approach and the
reducing cost of genotyping have generated their own
problems. A proliferation of studies of modest size,
and with apparently statistically signiﬁcant results, led
to a greater focus of thresholds for claiming statistical
signiﬁcanceandtoapreference,andlaterarequirement,
for replication studies to ‘conﬁrm’ an association. More
recently, with the advent of whole-genome association
arrays and very recent exome and whole-genome
sequencing studies, criteria for ‘statistical signiﬁcance’
are being assessed again. We remain in a transitional
stage where some journals will accept reports with
signiﬁcant levels as modest as p , 0.05, and others will
require replication studies and a ‘genome-wide signiﬁ-
cance’ level of p , 5  10
27 or less. This dramatic
difference in publication thresholds complicates review
of the ﬁeld as well as interpretation of results, as does
the long-standing [27] tendency for positive results to
be published more readily than negative ones.
Review. Genetics of infectious disease A. V. S. Hill 841
Phil. Trans. R. Soc. B (2012)4. CANDIDATE GENE STUDIES
I shall start with some examples of infectious disease
associations that appear convincing and are unusual,
in that the effect size is very large. All of these are effec-
tively candidate gene studies, in that the investigators
chose to assess these particular genes based on some
biological information rather than a genome-wide
scan.Iamawareofsixassociationsthataremajoreffects
[28], arbitrarily deﬁned as an odds ratio exceeding 3,
where the variant allele is polymorphic in some human
populations. These six (table 1) are all supported by
case–control analysis of allele and genotype frequencies
but, interestingly, three were discovered in a surprising
manner. The ﬁrst reports of the sickle haemoglobin
[1] and Duffy blood group associations [4] with malaria
resistance included analysis in deliberately infected
volunteers, as did the identiﬁcation of the importance
of the non-secretor status for blood group antigens,
determined by the fucosyltransferase (FUT2) gene, in
resistance to infection by norovirus [31], a frequent
viral cause of diarrhoeal disease. The ability to identify
these associations in small microbial challenge studies
reﬂects both the large effect sizes of these variants and
excellent biological insights suggesting the relevant
candidate gene.
In contrast, other candidate gene associations
(table 2) that appear compelling typically have smaller
effect sizes, with odds ratios of 0.5–2, but most of
these are still larger effects than are generally found
by genome-wide analyses of non-infectious diseases
(with the sole exception of HLA associations with
autoimmunity where occasional exceptionally strong
associations are seen).
It is impossible to review in any detail here the
plethora of reports of candidate genes that have now
been associated with various infectious diseases, and
there have been several recent reviews [28,42] and an
entire monograph on this subject [43]. Some of the
more compelling associations are listed in table 2,
with references. Instead, I will discuss some selected
candidates of immunological relevance that may impact
on the risk of disease from several infectious pathogens.
Associations with susceptibility to several infectious
diseases may of course increase the evolutionary
importance of speciﬁc genetic variants.
5. INNATE IMMUNE SIGNALLING PATHWAYS
An explosion of research in innate immunity over the last
decade has led to considerable clariﬁcation of the role of
Table 1. ‘The Big Six’ of human infectious disease genetics. All six genetic variants have a substantial impact (odds ratio . 3)
on risk of an important infectious disease and all are prevalent in at least one major human population group.
genetic variant/condition gene infectious disease year reported reference
sickle haemoglobin HBB Plasmodium falciparum malaria 1954 [1]
the Duffy blood group DARC Plasmodium vivax malaria 1976 [4]
prion protein gene variant PRNP Creutzfeldt–Jakob disease 1991 [29]
Melanesian ovalocytosis SLC4A1 P . falciparum malaria 1995 [30]
CC chemokine receptor-5 D32 CCR5 HIV-1 infection 1996 [2]
blood group non-secretion FUT2 Norwalk virus diarrhoea 2003 [31]
Table 2. Loci strongly associated with infectious disease susceptibility. For each gene–disease pair the table indicates
whether the association was identiﬁed by, or conﬁrmed by, a genome-wide association study (GWAS), whether the
association should be detectable by exome sequencing studies and whether the minor allele is associated with protection or
susceptibility (or whether different alleles are associated with protection and susceptibility ¼ ‘both’).
gene disease GWAS? exomic? minor allele reference
haemoglobin S malaria yes protective [1]
SLC4A1 (ovalocytosis) malaria yes protective [30]
CCR5 HIV/AIDS yes protective [2]
PRPN vCJD yes protective [29]
FUT2 norovirus yes protective [31]
Duffy blood group vivax malaria no protective [4]
HLA-DR/DQ leprosy conﬁrmatory yes both [32]
HLA-B HIV/AIDS conﬁrmatory yes both [33]
HLA-DQ/DP HBV yes yes both [34]
HLA-C HIV/AIDS conﬁrmatory yes both [33]
blood group O malaria yes protective [35]
G6PD malaria yes protective [36]
CFH meningococcus conﬁrmatory yes protective [37]
MAL bacteraemia yes protective [38]
TLR1 leprosy conﬁrmatory yes protective [39]
IL-28B HCV yes yes susceptible [40]
MBL2 pneumococcus yes susceptible [41]
C13orf31 leprosy yes susceptible [32]
CCDC122 leprosy yes protective [32]
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mation and acquired immunity [44]. The toll-like
receptor (TLR) signalling pathway has been the best
characterized leading to a particular emphasis on poly-
morphisms in this pathway by genetic studies. A striking
example is the prevalence of a variant of one of the four
TLR signalling adaptors, named MAL (encoded by the
gene TIRAP ) in many populations [38]. This appears
to be a functional knockout allele, and heterozygotes
have been reported to have an approximately twofold
reduction in risk of several infectious diseases, including
pneumococcal disease, tuberculosis and malaria [38].
The homozygous genotype is rare in many populations
but in Europe, where this genotype is less uncommon,
homozygotes may be at a slightly increased risk of
bacterial disease [38]. If so, this surprising genotypic pat-
tern could contribute to the evolutionary maintenance
of this polymorphism over long periods of time.
Another example of an immunological gene that
impacts on multiple infectious diseases was reported
recently. Cytokine-inducible SRC homology 2 domain
protein (CISH) was the ﬁrst member of the regulatory
suppressor of cytokine signalling (or SOCS) family to
be described, and CISH is the gene most consistently
upregulated by interleukin (IL)-2 stimulation in
humans, and is a key negative regulator of cytokines,
especially IL-2. Single-nucleotide polymorphisms
(SNPs) ﬂanking the promoter of this gene were associ-
ated with risk of bacteraemia, tuberculosis and severe
malaria in diverse populations and at least one of these
SNPs was shown to be functionally relevant [45].
A coding change at position 602 in the TLR1
protein, a key innate receptor component for many
bacteria, was shown to impact on the ability of this
receptor to reach the cell surface. The variant is
found at low frequencies in Africa, but is the more fre-
quent allele in many Caucasian populations. This
variant has recently been associated with a substantial
reduction in risk of leprosy in Turkey and India, with
the cumulative data reaching impressive statistical sig-
niﬁcance (p , 10
27)[ 39,46]. Intriguingly, the same
variant was associated with a reduced risk of tubercu-
losis in an exon resequencing study of TLR genes in
African Americans [47]. So this may provide another
example of a variant impacting on several diseases,
and in this case, there is suggestive evidence that the
protective variant may have increased in frequency by
providing protection against mycobacterial disease.
Finally, one of the best studied genes impacting on a
widevarietyofautoimmunediseasesisthelymphoidtyro-
sine phosphatase (Lyp) gene, PTPN22. An R620W
change is common in Europeans and increases the risk
of type I diabetes, rheumatoid arthritis, systemic lupus
erythematosus and several other autoimmune diseases
[48]. Interestingly, the same variant was associated with
an increased risk of invasive pneumococcal disease and
empyema (a form of suppurative lung disease) [49]a n d
very recently with leprosy in India [50]. Although it
might be expected that alleles associated with an
increased risk of autoimmunity might protect against
infectious diseases, in this case the observed association
is in the opposite direction.
Many other infectious disease associations with
genetically variable components of the innate and
acquired immune systems are appearing. Several, such
as the relevance of variants in genes encoding inhibitors
for NFkB signalling [51–53], have been studied only in
a small numberof infections (in this case pneumococcal
disease), and more extensive surveys of infectious dis-
eases are justiﬁed. The challenge continues to be
accessing large well characterized clinical series with
suitable controls to allow adequately powered studies.
In summary, just asHLA genesmay impacton riskof
severalinfectious diseases aswell asautoimmunity, there
are now several examples of non-HLA loci that also
appearrelevanttomultipleinfectionsaswellasexamples
ofrare monogenicvariantsthatimpactonthe riskofsev-
eral infectious diseases [54]. The consequences of this
for evolutionary change in allele frequencies over time
will undoubtedly be complex. Not only will selection
pressures ﬂuctuate with the prevalence and strain of
infectious pathogens (see below), but the presence of
different pathogens might have either opposing or addi-
tive impacts on the change in allele frequencies of
particular genetic variants.
6. GENOME-WIDE ASSOCIATION STUDIES
The introduction of genome-wide association studies
(GWAS) has revolutionized the ﬁeld of complex disease
genetics. The availability of millions of SNPs mapped
across the human genome and of microarrays that allow
cost-effective genotyping of millions of SNPs in thou-
sands of individuals provided, for the ﬁrst time, the
opportunity to test fairly comprehensively for genetic
markers that would tag causative variants [55]. In many
diseases, the yield of this approach has been spectacular,
withhundredsoflocinowidentiﬁedin,forexample,auto-
immune diseases. This is providing new insights into the
molecular pathogenesis of these diseases as a route to
designing and developing new treatments. There is also
potential value in devising diagnostic arrays that would
allow some prediction of risk of certain diseases.
Despite these spectacular successes, there are limit-
ations to this approach. Even in the diseases where
many dozens of loci have been identiﬁed and replicated,
theproportionoftheestimatedgeneticvariancethatcan
be explained by all the identiﬁed genetic associations is
modest, often less that 20 per cent of the total genetic
variancessuggestedbytwinstudies[56].Thisisbecause
the individual associations are generally of modest
magnitude, with odds ratios typically of 1.1 to 1.5. Fur-
thermore, there is little evidence of epistatic interactions
between loci that could account for some of the missing
geneticcomponent.Searches for structuralvariantsthat
mightaccountfor themissingcomponenthavemetwith
little success. The leading current hypothesis to explain
the missing component is that rare variants, perhaps
with larger effect sizes, are cumulatively responsible
[56], but because of their low frequencies these are
very poorly assessed with available GWAS microarrays.
For infectious diseases, the picture is yet more com-
plicated. Fewer diseases have been studies by GWAS,
in part because the approach requires very large
sample sizes to be worthwhile. This results from the
very large number of SNPs assayed, leading to a major
challenge in sorting true signals from the noise or false
positives that inevitably turn up when assaying about a
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replication of positive signals and to use a challenging
threshold level of ‘genome-wide’ statistical signiﬁcance
of about p ¼ 5  10
27. This requirement for typically
thousands of cases and suitable matched controls has
limited GWAS studies of infectious diseases. Despite
the high prevalence of many infectious diseases in
developing countries, resource limitations still make it
harder to collect 2000 tuberculosis cases in West
Africa than 20000 diabetes cases in western Europe.
A further challenge is found in studies of African popu-
lations, which were among the ﬁrst to be studied by
GWAS for infectious diseases, as part of the Wellcome
Trust Case–Control Consortium [57,58]. The shorter
extent of linkage disequilibrium in Africans compared
with non-Africans leads to a requirement for larger
numbers of SNPs to attain the same coverage of the
genomeasinCaucasianandAsianpopulations. Greater
diversity in populations in Africa and complexities in
haplotype structure may also complicate ﬁne mapping
of causative SNPs (ﬁgure 1)[ 58].
Nonetheless, several GWAS studies of infectious
diseases have been undertaken with some notable suc-
cesses. In Africa, a combined analysis of tuberculosis
cases from The Gambia and Ghana identiﬁed a sig-
nal with genome-wide signiﬁcance on chromosome
18 [57]. Although this region is gene-poor, a ﬂanking
gene that encodes the transcription factor GATA6 is
an excellent positional candidate for tuberculosis.
Another signal was found on chromosome 2 in the
PARD3B cell polarity gene [57], which interestingly
also emerged from a GWAS of HIV disease progression
[59] (although the associated regions of the gene in the
two studies are different). Further statistical analysis of
the tuberculosis GWAS datasets using an imputation
technique to estimate association with less well-covered
genomic regions has identiﬁed a further highly signi-
ﬁcant signal [60]. A parallel GWAS study of malaria in
Gambians identiﬁed the haemoglobin AS variant with
clear statistical signiﬁcance but highlighted the chal-
lenges of using limited microarray coverage to map
even such strong hits in Africans [58]. A very striking
positive association was reported for hepatitis C where
one of the interferon lambda genes, IL-28B, showed a
striking association with viral clearance and with
response to treatment [40].
But probably the most marked GWAS success in
infectious diseases has been a study of leprosy reported
by a Chinese group [32]. By studying about 4000 cases
and 7000 controls, ﬁve new genes showed strongly sig-
niﬁcant associations (p , 10
210) in addition to the
expected HLA class II region association. Three of
these six genes could be replicated in an independent
study of Indian patients with leprosy [61]. Most inter-
estingly, the susceptibility genes identiﬁed in Chinese
leprosy show a striking overlap with genes previously
associated with Crohn’s disease [32]. Although this
does not necessarily implicate mycobacteria in the
aetiology of Crohn’s disease, a theory for which there
is some support [62], this does point to the same path-
ways, related to NOD2 signalling, being relevant in
these two granulomatous diseases.
In contrast, large GWAS efforts in HIV/AIDS have
been less successful [63]. Although the associations in
the HLA class I regions with rate of progression
to AIDS were reconﬁrmed and well mapped, no con-
vincing new associations were identiﬁed in other
chromosomal regions [33,64]. However, these GWASs
of disease progression have been limited to non-African
populations and studies in the continent most affected
by the epidemic and with the greatest human gen-
etic diversity should still be worthwhile. Similarly, a
somewhat smaller GWAS in meningococcal disease
conﬁrmed an association with the complement factor
H( CFH) gene, previously identiﬁed in a candidate
gene study of this disease [37]. And in malaria a ﬁrst
GWAS in Gambians failed to identify new loci with
genome-wide signiﬁcance [58], although large-scale
GWASs in other African populations are continuing as
part of the extensive MalariaGEN consortium [65].
7. GENETIC ARCHITECTURE OF INFECTIOUS
DISEASES
Thelimitedsuccess,atleasttodate,ofGWASapproaches
ininfectiousdiseasesraisesthequestionofwhether thisis
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Figure 1. Association plot of the main associated locus identiﬁed in combined analysis of genome-wide association studies of
tuberculosis in The Gambia and Ghana. The y-axis show the negative log of the p-value for the association test. The peak of
association is in a gene-poor region, but the positions of ﬂanking genes are shown. Adapted from Thye et al.[ 57].
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underlying variable susceptibility. Indeed, for many
non-infectious diseases the ﬁeld is moving towards
next-generation sequencing approaches to try to identify
the genes accounting for the heritability not identiﬁed
through GWAS. This discussion raises the key question
ofthegeneticarchitectureofvariablesusceptibilitytodis-
ease (table 3). There are at least three competing views.
GWAS analysis was based on the hypothesis that most
of the genetic component to common diseases can be
explained by common variants; this is sometimes
dubbed the common disease–common variant hypothe-
sis [66]. Because GWAS relies on linkage disequilibrium
between common genotyped markers and relatively
common causative variants, it has inadequate power to
detectsigniﬁcantassociationswithrarecausativevariants.
The second hypothesis listed in table 3 is that rare mono-
genic variants with high penetrance account for the bulk,
or all, of the genetic component to common disease [67].
Although this may sound implausible, given the lack of
Mendelian inheritance of most common disease, it has
been seriously proposed for at least paediatric infectious
diseases [68]. This idea emerged from the primary
immunodeﬁciency disease ﬁeld where it has been fairly
straightforward to identify some causal mutations by
sequencing of candidate genes in rare pedigrees with
familial severe susceptibility or rare novel mutations.
Emboldened by success with these rare phenotypes, one
group has suggested that the same monogenic major
gene genetic architecture underlies common infectious
disease phenotypes [68,69].
A newer and more plausible third hypothesis (table 3)
is advocated here for infectious diseases. This is the
concept that much of the genetic component to
common infectious disease may be accounted for by the
cumulative effects of many rare mutations with limited
penetrance [66]. While, in this view, rare mutations
would account for much of the genetic component, a
consensus view would allow for hypothesis 1 to also be
partly true, with common variants accounting for part
of the genetic component: of course, there is good evi-
dence that this is the case for many diseases (as
reviewed earlier). Finally, one should allow that rare
familial cases of severe susceptibility, usually in young
children, can indeed be Mendelian as has been docu-
mented in selected rare cases [67]. However, the lack
of evident Mendelian transmission in most cases of
infectious disease susceptibility and the evolutio-
nary consideration that severe deleterious mutations
should be rapidly eliminated from populations indicates
that the contribution of highly penetrant deleterious
mutations to the great majority of infectious disease
cases must be very limited.
There is a practical relevance to the understanding of
which genetic architecture is most correct. If common
variants are of over-riding importance, an extension of
theGWASapproach,withmicroarraysofimprovedcov-
erage and analysis of larger sample sizes, might be the
best way forward. But if rare variants account for most
susceptibility, sequencing approaches will be required.
Fortunately, next-generation sequencing costs continue
tofallrapidlyandpromisetoallowhypotheses2and3to
be assessed in the foreseeable future.
8. TOWARDS EXOMICS
Sequencing costs remain a major limitation today and,
even though whole genome sequencing of over three tril-
lion base pairs is feasible, the costs of full genomic
sequencingofthousandsofsamplesinjustoneinfectious
disease are still prohibitive. Fortunately, sequencing of
just the exome, composed of all the exons in the
genome, and some limited exon ﬂanking sequence,
might provide a cost-effective alternative [70–72]. This
is feasible using a variety of capture matrices. The
exome comprises just one per cent of the human
genome, and costs per sample are falling rapidly from
thousands to hundreds of pounds per sample. Although
costs will still be high initially, a limited number of
samples can be sequenced for the full exome, to search
for suggestive associations, and these can be reassessed
in a replication study by more limited sequencing of
genes of interest on larger sample numbers. As well as
analysing individual mutations, the mutational load in a
gene,comprisingthefullsetofcodingchangesidentiﬁed,
can be compared between cases and controls.
Initial data on exon sequencing in infectious dis-
eases are encouraging. Smirnova et al.[ 73] focused
on the TLR4 gene in meningococcal disease and ident-
iﬁed a substantial excess of rare coding changes in
cases compared with those in controls, with a remark-
ably large suggested effect size. Ma et al.[ 47] studied
ﬁve TLR genes and again found an excess of rare
(and some more frequent) coding changes in tubercu-
losis cases compared with controls.
An argument against focusing on exons is that when
one reviews the variants that have been associated with
non-infectious disease susceptibility using GWAS
analyses, there is strong evidence that the majority of
changes identiﬁed are regulatory or at least non-coding
changes [55]. If this is also true of infectious diseases,
then exome sequencing could miss most of the relevant
Table 3. Theories of the genetic architecture of human
infectious disease susceptibility. Theory 1 suggests that
most relevant genetic variation is encoded by relatively
common variants that cumulatively account for most of the
genetic variance. Theory 2, in complete contrast, is the
extreme view that most relevant genetic variation is encoded
by very rare new mutations that have almost complete
penetrance, as in primary immunodeﬁciency diseases. The
more recent theory 3 suggests a predominant role for many
individually rare variants with incomplete penetrance,
which are generally not new mutations, but cumulatively
account for most of the genetic component to infectious
disease susceptibility.
genetic architecture of infectious diseases susceptibility:
three theories
1 common variants
higher frequency variants
identiﬁable by genome-wide association scans
2 very rare monogenic variants
highly penetrant mutations
mainly novel mutations
3 multiple rare diverse variants
not fully penetrant
mainly standing genetic variation
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ent for infectious diseases, based on review of the
available data on known associations. Table 2 lists the
majority of the most convincing associations with infec-
tious diseases where the causative genetic changes are
bothpolymorphicinhumanpopulationsandreasonably
welldeﬁned.Itisstrikingthatinsixteenoutofseventeen
cases, the association could have been identiﬁed by
exome sequencing. Either the mutation is in an exon
or, as in the case of the IL-28B–hepatitis C association,
a change in an exon tracks very well a ﬂanking (possibly
regulatory) change. This excess of exonic changes
contrasts strikingly with GWAS-identiﬁed changes in
sayautoimmunediseases.Aseconddifferenceisalsoevi-
dent. In most GWAS studies of non-infectious diseases,
the minor allele is associated with an increased risk of
disease whereas, as indicated in table 2, there are more
examples of protective than susceptible minor alleles in
infectious disease associations.
There are many possible reasons for these striking
differences, including some differences in ascertain-
ment methods, but if these differences are real a likely
contributor is the action of natural selection by infec-
tious pathogens. In well-studied examples, such as
malarial selection of haemoglobin S, it is clear that the
protective minor allele has reached polymorphic
frequencies by conferring a survival advantage to car-
riers. Similar mechanisms can be invoked for most of
the changes listed in table 2, but any such selection
pressures on alleles that impact on non-infectious
diseases would probably be far weaker.
Whatever the cause of the apparent excess of
changes in exons associated with infectious diseases,
arguably such coding changes are the associations
one would most like to uncover, both to understand
disease pathogenesis and also to provide further
examples of selective pressures by infectious pathogens
on human genetic diversity.
In conclusion, the new technology of exome sequen-
cing offers an attractive approach to searching for
numerous rare sequence changes that may associate
with disease susceptibility. Moreover, initial data
suggest that the impact (or effect sizes) of these uncom-
mon coding changes may be greater than those of the
higher frequency non-coding polymorphisms that are
generally identiﬁed in GWAS.
9. NATURAL SELECTION AND INFECTIOUS
DISEASE SUSCEPTIBILITY GENES
Case–control studies have provided the strongest evi-
dence of ongoing selection by infectious pathogens on
genetic polymorphism in humans. Less direct evidence
of selection is provided by a variety of other statistical
approaches to the analysis of genomic data, some of
which are described in other chapters of this issue. A
recent developmentisthe useof acomposite ofmultiple
signals that can pinpoint variants likely to have under-
gone selection [74]. These regions and SNPs can then
be prioritizedforanalysisin case–control studiesofpar-
ticular infectious diseases, illustrating the potential
complementarity of these approaches.
However, some caveats in each approach should be
noted. Some signals of selection extant in our genomes
will have been generated by pathogens or strains of
pathogens that have died out or been eradicated, pre-
venting case–control studies of their effects, although
in vitro studies or animal models might still allow some
analysis and inferences. Conversely, the temporally
varying natural history of epidemics and ever-varying
genetic diversity of pathogens may tend to minimize
signals of selection in our genomes, particularly when
compared with the more continuous effects of other
selective agents such as sunlight and climate. In this
context, it is worth recalling that at least three types of
selectionhavebeendemonstratedtobecapableofmain-
taining genetic diversity in humans over long periods of
evolutionarytime,asiswellillustratedbyconsiderationof
the maintenance of the extraordinary diversity of HLA
genes in the human major histocompatibility complex.
Although heterozygote advantage [75] and frequency-
dependent selection [76,77] are the most frequently
invoked modes of selection capable of maintaining
polymorphic diversity, ﬂuctuating selection pressures
[76,78] (varying either spatially or temporally, or both)
are also capable of maintaining polymorphism. Indeed,
epidemiological records provide powerful evidence that
ﬂuctuating selection by lethal infectious pathogens is
commonplace in recent human history and may always
have been so, at least since the increase in population
densities following the introduction of agriculture.
Such ﬂuctuation in selection pressures will result not
just from the transient occurrence of particular epi-
demics but from temporal and spatial changes in the
antigenic composition of pathogens, as different strains
are likely to interact differentially with particular host
resistance genotypes. The impact on signatures of selec-
tion [79], as currently deduced from genomic sequence
data, could be profound in that short periods of selec-
tion and then a reversal of the selection pressure
would tend to minimize any detectable signals in the
genome over time. As discussed earlier, several host
genes affect resistance to multiple infectious pathogens
and this too could tend to weaken signals if different
pathogens interact differentially with various host geno-
types. The overall effect of these complexities is that
many statistical searches for genomic signatures of
selection may underestimate the evolutionary impact
of infectious pathogens, because of the complexity of
selection involved, in contrast to simple directional
selection pressures provided by some other factors
such as climate or dietary change.
AmajorinterestoftheDiscussionMeetingthatledto
this publication has been the use of human genetic var-
iants as markers of migration routes and population
differentiation in recent human evolution. Although
some theoretical considerations would point to a prefer-
ence for non-selected markers for this purpose, in
practice, variants that have clearly been selected by
infectious pathogens have proved very useful for tracing
migration and population afﬁnities. These include
examples from the highly polymorphic HLA genes
[80], and also speciﬁc haemoglobinopathies that were
selected to high frequency by malaria but subsequently
could be used to trace population migrations. For
example, a speciﬁc alpha globin gene deletion in the
southwest Paciﬁc helped early genetic studies of
the colonization of Oceania [81].
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received most attention by human geneticists and
those that have produced the clearest successes pro-
vides a striking outlier. HIV, tuberculosis and malaria
have probably had most investment and attention, in
accordance with their global public health burden,
but the star performer in terms of results must be
leprosy. This was the ﬁrst infectious disease shown to
be HLA-associated [82], the most successful disease
for mapping loci by linkage analysis [18–20] and, to
date at least, the most successful example of a
GWAS [32]. In the past, this may have reﬂected
easier sample collection for leprosy but this is no
longer the case. A more likely explanation may relate
to the extreme lack of genetic polymorphism in the
causative bacterium, Mycobacterium leprae, which has
now been well documented by whole genome sequen-
cing [83]. If this explanation is correct, then the
implications may be profound. Many of the difﬁculties
in mapping and identifying strong genetic factors for
human infectious diseases may relate to the ‘pooling’
of genetically diverse strains of a single pathogen in
studies of a single infectious disease. Hence, separating
out cases according to strain or genotype of the patho-
gen may increase power to detect strain-speciﬁc host
effects, and already there is some preliminary evidence
that pathogen strain may inﬂuence infectious disease
associations [84]. Now that full genome sequences of
viral, bacterial and even some protozoan pathogens
can be determined routinely, such an approach is
becoming more feasible. Allowing for strain diversity
in host genetic studies will undoubtedly increase com-
plexity and the required sample sizes but may be
particularly rewarding for studies of immunogenetic
polymorphisms.
The study of the genetics of infectious disease sus-
ceptibility has undergone revolutionary change over
the last decade, driven by spectacular advances in
human genomics, and the rate of progress shows no
sign of abating. Fascinating insights have been uncov-
ered into the long battle between pathogens and their
human host and the consequences for our genetic heri-
tage. Although our power to understand and control
major infectious pathogens is greater than ever, the
true scale of the challenge posed by our need to main-
tain a long-term accommodation with the microbial
world is only beginning to be appreciated.
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